Biocartis Group NV

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
  • TickerA14R82
  • ISINBE0974281132
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium

Analysts

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: BCART BB, GREEN BB

Biocartis: Venture into cell therapies with Kite/Gilead Greenyard: Sale of Greenyard Frozen Hungary

Alan Vandenberghe ...
  • Alexander Makar
  • Cedric Duinslaeger
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: AED BB, ASC BB, BCART BB, CPINV BB, IVA FR, NN NA, RTL BB, SBMO NA, SLIGR NA

Aedifica: 3Q18-19 results Ascencio: Renewal of leases with Grand Frais Biocartis: Presenting MSI results at ASCO CP Invest: 1Q19 results: slightly above expectation Inventiva: 1Q19 business update NN Group: 1Q bottom line well ahead, but underlying lacklustre RTL Group: Beat driven by Fremantle, broadcast not as bad SBM Offshore: Good 1Q19 update, no surprises Sligro: Feedback CMD in Antwerp

Alexander Makar ...
  • Bart Cuypers
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: ASIT BB, BALTA BB, BCART BB, COFB BB, OPTI BB , ELI BB, FFARM NA, INGA NA, KDS NA, MTLS US, SMAR BB, TNET BB, UCB BB

ASIT biotech: CFO appointed. Last treatment visit in repeat phIII Balta: Preview 1Q – easy margin comparable Biocartis: Issuance of € 125m in convertible bonds Cofinimmo: 2nd in a row - € 50m investment in Germany Crescent: Postponement of FY18 results till 20 May Elia Group: Belgian development plan and renewal TSO status ForFarmers: 1Q19: temporary unfavourable purchasing positions ING: 1Q 19: Costs and Fees not supporting guidance yet Kiadis: Phase III and debt repayment weigh on cash burn Materialise: On track to meet its financial guidance for FY19 Smartphoto group: Start of a share buy-b...

Hugo Solvet

BIOCARTIS: Q1’19 business update: FY’19 guidance reiterated | BUY | EUR17(+42%)

BIOCARTIS - BUY | EUR17(+42%) Q1’19 business update: FY’19 guidance reiterated Installed base continues to grow FY’19 guidance reiterated, uptake expected from Q2 onwards EUR100m in cash at hand implies H2’20 financial runway Staffing of key positions

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: BAR BB, BEKB BB, BCART BB, MITRA BB, WES NA

Barco: Extending its partnership with IMAX Bekaert: Read-through Michelin 1Q trading update Biocartis: All guidance reiterated Mithra: Myring – exclusive license Latin/South America Wessanen: Appoints new CFO

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: BCART BB, GREEN BB

Biocartis: Venture into cell therapies with Kite/Gilead Greenyard: Sale of Greenyard Frozen Hungary

Alan Vandenberghe ...
  • Alexander Makar
  • Cedric Duinslaeger
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: AED BB, ASC BB, BCART BB, CPINV BB, IVA FR, NN NA, RTL BB, SBMO NA, SLIGR NA

Aedifica: 3Q18-19 results Ascencio: Renewal of leases with Grand Frais Biocartis: Presenting MSI results at ASCO CP Invest: 1Q19 results: slightly above expectation Inventiva: 1Q19 business update NN Group: 1Q bottom line well ahead, but underlying lacklustre RTL Group: Beat driven by Fremantle, broadcast not as bad SBM Offshore: Good 1Q19 update, no surprises Sligro: Feedback CMD in Antwerp

Alexander Makar ...
  • Bart Cuypers
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: ASIT BB, BALTA BB, BCART BB, COFB BB, OPTI BB , ELI BB, FFARM NA, INGA NA, KDS NA, MTLS US, SMAR BB, TNET BB, UCB BB

ASIT biotech: CFO appointed. Last treatment visit in repeat phIII Balta: Preview 1Q – easy margin comparable Biocartis: Issuance of € 125m in convertible bonds Cofinimmo: 2nd in a row - € 50m investment in Germany Crescent: Postponement of FY18 results till 20 May Elia Group: Belgian development plan and renewal TSO status ForFarmers: 1Q19: temporary unfavourable purchasing positions ING: 1Q 19: Costs and Fees not supporting guidance yet Kiadis: Phase III and debt repayment weigh on cash burn Materialise: On track to meet its financial guidance for FY19 Smartphoto group: Start of a share buy-b...

Hugo Solvet

BIOCARTIS: Q1’19 business update: FY’19 guidance reiterated | BUY | EUR17(+42%)

BIOCARTIS - BUY | EUR17(+42%) Q1’19 business update: FY’19 guidance reiterated Installed base continues to grow FY’19 guidance reiterated, uptake expected from Q2 onwards EUR100m in cash at hand implies H2’20 financial runway Staffing of key positions

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs

Morning Note: BAR BB, BEKB BB, BCART BB, MITRA BB, WES NA

Barco: Extending its partnership with IMAX Bekaert: Read-through Michelin 1Q trading update Biocartis: All guidance reiterated Mithra: Myring – exclusive license Latin/South America Wessanen: Appoints new CFO

A director sold 10,000 shares at 14.040EUR and

A director at Biocartis Group Nv sold 10,000 shares at 14.040EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 10 May 2019

In general, BIOCARTIS is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting.  Under ITEM 6, the board of directors seeks approval of the Company's remuneration report. Although amounts at stake are very moderate compared to sector and market practice, ECGS has concerns over the poor disclosure of the company and the lack of LTI component. Thus ECGS recommends to vote OPPOSE.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch